Drug Watch: Agents in late-stage development for the treatment of type 2 diabetes mellitus (August 2008) (PDF)

If approved, Wegovy would be the first oral GLP-1 drug to treat obesity.

Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Insurance hurdles and the complexities of prior authorization create barriers to care, according to oncologists in a new survey by Sermo.

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg through its NovoCare Pharmacy.

Giant Eagle also helped EmpiRx Health create a national pharmacy care network that was purpose-built for pharmacy and grocery chains.